A new type of treatment for osteoarthritis, currently in canine clinical trials, shows promise for eventual use in humans.
The treatment, developed by Cornell biomedical engineers, is a synthetic version of a naturally occurring joint lubricant that binds to the surface of cartilage in joints and acts as a cushion during high-impact activities, such as running.
“When the production of that specific lubricant goes down, it creates higher contact between the surfaces of the joint and, over time, it leads to osteoarthritis,” said David Putnam, a professor in the College of Engineering with appointments in the Meinig School of Biomedical Engineering and the Smith School of Chemical and Biomolecular Engineering.
Putnam is senior author of “Boundary Mode Lubrication of Articular Cartilage With a Biomimetic Diblock Copolymer,” published June 4 in Proceedings of the National Academy of Sciences, USA. Zhexun Sun, a postdoctoral researcher in Putnam’s lab, is the paper’s first author.
The study focuses on a naturally occurring joint lubricant called lubricin, the production of which declines following traumatic injuries to a joint, such as a ligament tear in a knee.
The knee is lubricated in two ways – hydrodynamic mode and boundary mode.
Hydrodynamic mode lubrication occurs when the joint is moving fast and there isn’t a strong force pushing down on it. In this mode, joints are lubricated by compounds like hyaluronic acid (HA) that are thick and gooey, like car oil. There are numerous HA products on the market, approved by the Food and Drug Administration, for treating hydrodynamic mode lubrication disorders.
But HA is ineffective when strong forces are pushing down on the joint, such as those that occur during running or jumping. In these instances, thick gooey HA squirts out from between the cartilage surfaces, and boundary mode lubrication is necessary. Under these forces, lubricin binds to the surface of the cartilage. It contains sugars that hold on to water, to cushion hard forces on the knee.
In the paper, the researchers describe a synthetic polymer they developed that mimics the function of lubricin and is much easier to produce. “We are in clinical trials, with dogs that have osteoarthritis, with our collaborators at Cornell’s College of Veterinary Medicine,” Putnam said.
Those collaborators – Ursula Krotscheck and Kei Hayashi, both associate professors in the Section of Small Animal Surgery in the Department of Clinical Sciences – use a force plate to measure the efficacy of the treatments. The force plate quantifies the amount of force that a dog exerts with each paw, to measure whether they are favoring one paw over another.
“Once we finalize the efficacy study in dogs, we will be in a very good position to market the material for veterinary osteoarthritis treatment,” Putnam said. From there, the human market for a lubricin substitute should follow, just as HA has been made available for human use, mainly in knees.
The Latest on: Osteoarthritis
via Google News
The Latest on: Osteoarthritis
- Stick to supportive shoes if you have knee painon January 12, 2021 at 5:23 am
A randomized controlled trial found that sturdy supportive shoes improve knee pain on walking and knee-related quality of life compared with flat flexible shoes. This evidence supports recommendations ...
- 17 Herbs to Try for Mind and Body Benefits, Says Scienceon January 12, 2021 at 2:46 am
To remedy minor ailments, forego the pharmaceuticals and give natural nutraceuticals a try—these are the herbs and dosages that are proven to work.
- Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For ...on January 12, 2021 at 1:43 am
RMAT Designation Enables Closer FDA Interactions to Support Accelerated Approval CANTON, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative ...
- Study reveals new link to arthritison January 11, 2021 at 8:32 am
A new study by investigators at the Shriners Hospital for Children—St. Louis suggests the damaging effects of obesity are not due to body weight but rather come from something much smaller—biochemical ...
- Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis of the Kneeon January 11, 2021 at 6:22 am
FDA Determines ReNu Preliminary Clinical Evidence Indicates Potential to Address Unmet Medical Needs for the Management of Symptoms Associated ...
- Arthritis symptoms: Pain felt in the middle of the night could be a sign of osteoarthritison January 10, 2021 at 1:35 pm
ARTHRITIS can attack any joint in the body, including those in the feet. How can you tell the difference between achy tootsies or osteoarthritis? Especially as the condition can affect anyone at any ...
- The impact of COVID-19 on Osteoarthritis Pain Drugs Market 2021 Global Industry Trends, Growth, Share, Size and 2026 Forecast Research Reporton January 7, 2021 at 9:49 pm
The Osteoarthritis Pain Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, ...
- Shriners Hospitals for Children study reveals new link to arthritison January 7, 2021 at 9:00 pm
A new study by investigators at the Shriners Hospital for Children -- St. Louis suggests the damaging effects of obesity are not due to body weight but rather come from something much smaller - ...
- Osteoarthritis Drug Market Investment Analysis With COVID-19 Outbreak Effect | Pfizer Inc, Horizon Pharma plcon January 7, 2021 at 7:34 am
A consciously conceived and designed business intelligence report titled Global Osteoarthritis Drug market 2021 ...
- Global Osteoarthritis Therapeutics Market (2020 to 2025) - Personalized Medicines for Osteoarthritis Presents Opportunitieson January 5, 2021 at 6:15 am
The "Global Osteoarthritis Therapeutics Market by Anatomy (Knee, Hand), Drug Type (NSAIDs, Analgesics, Corticosteroids), Route ...
via Bing News